Rafaella’s Literature Update

Dear Friends, Regulatory agencies are responsible for collecting and evaluating spontaneous reports of suspected problems related to medications, including those from substandard medicines (SM). As the first mailing of 2022, I am sharing the attached article (Fedalto et al. Reports of substandard medicines: a lexicographic analysis of the Brazilian Health Surveillance Report System. Rev Ciênc ...

Rafaella’s Literature Update

Access to antivenoms in the developing world: a multidisciplinary analysis Dear Friends,   Even if the majority of us is probably not involved in procurement or management of antivenoms, I think the attached paper remains of great interest, for raising awareness of a very neglected access problem. It examines some of the most relevant barriers to access ...

Rafaella’s Literature Update

Online event: “Technologies to Tackle Substandard and Falsified Medical Products in Global Health” Dear Friends,  With apologies for any double posting, I am forwarding on behalf of Kate Enright the information concerning this upcoming online event. Please note that it is organized in a way that may give also to non-academic actors (e.g., those working ...

Rafaella’s Literature Update

Dear Friends, As we know, substandard and falsified (SF) medical products negatively affect patients’ safety and health outcomes, health systems’ financial sustainability, public trust in health systems, and they are a co-cause of antimalarials and antimicrobial resistance. Therefore, sound research on SF medical products is important in order to raise awareness, to understand the causes ...

Raffaella’s Literature Update:

210923 BCH/QUAMED: Quality of medical products for cardiovascular diseases Ref: Do NT, Bellingham K, Newton PN, et al. The quality of medical products for cardiovascular diseases: a gap in global cardiac care. BMJ Global Health 2021;6:e006523. doi:10.1136/bmjgh-2021-006523 Dear Friends, Today, I would like to share an important research paper from our IDDO friends in Oxford. The ...

RAFAELLA’S LITERATURE UPDATE

Be-cause Health & QUAMED literature updates Ref: World Health Organization. Regulatory guidance for assessment and management of applications for marketing authorization of oxytocin. WHO 2021. ISBN 978-92-4-002213-3 (electronic version). Dear Friends, Today, I would like to share a WHO regulatory document concerning the quality of oxytocin-containing products. You can download it at this link: https://www.who.int/publications/i/item/9789240022133 ...

Rafaella’s Literature Update

Be-cause Health & QUAMED literature updates Ref (1): US Pharmacopoeia, Increasing Transparency in the Medicines Supply Chain, 2021 Ref (2): US Pharmacopoeia, Global Public Policy Position: Key Elements to Building a More Resilient Supply Chain Dear Friend, The more diffuse and fragmented the supply chain is, the greater the risk that important information about the origin, production ...

Rafaella’s Literature Update

Be-cause Health & QUAMED literature updates ·         Ref. Bourasseau, A., Lavergne, L. & Ravinetto, R. Assessments of the quality systems of pharmaceutical distributors: a remote approach to be applied in times of COVID-19 and beyond. J of Pharm Policy and Pract 2021; 14, 43 Dear Friend, Today, I would like to present a very recent publication, which just appeared in ...

RAFAELLA’S LITERATURE UPDATE

Be-cause Health & QUAMED literature updates Ref. Tuck C et al.  Quality assurance and cancer medicines in low-income and middle-income countries. Lancet Oncol 2021; 22: 301-3. Available at https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00055-3/fulltext?rss=yes Dear Friend, I would like to highlight a short but important commentary from Tuck and colleagues, raising awareness on the quality challenges for cancer medicines available in ...

Raffaella’s literature update

Be-cause Health & QUAMED literature updates Ref Hauk C, SchafermannS, Martus P, Muzafarova N, Babaley M, Waning B, et al. (2020) Quality assurance in anti-tuberculosis drug procurement by the Stop TB Partnership—Global Drug Facility: Procedures, costs, time requirements, and comparison of assay and dissolution results by manufacturers and by external analysis. PLoS ONE 15(12): e0243428.  ...